UCT-03-008 / 1200 Pharma - LARVOL DELTA

Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers (AACR 2023) - P1 | "We evaluated the clinically approved CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib—in a 500+ cell line screening platform and identified several cancers outside of breast that may have subpopulations that are sensitive to CDK4/6 inhibitors. Clinical development of this compound will be guided by the biomarker hypotheses developed here. We are currently enrolling patients for treatment with UCT-03-008 in a Phase 1 clinical trial of advanced solid tumors (NCT05103046)."

Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ER • HER-2

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=68 | Recruiting | Sponsor: 1200 Pharma, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor